Therapy News and Research

RSS

Testosterone therapy for prostate cancer needs reevaluation: New study

The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology.

20 Apr 2011

Whole-genome sequencing could soon improve cancer survival rates

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

20 Apr 2011

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Scientists detect several biomarkers to screen active drugs for Batten disease

Goethe University and Harvard Medical School start screening for active ingredients for the treatment of Batten disease

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

Flexibility of the brain can predict learning capability

An international team of scientists has developed a way to predict how much a person can learn, based on studies at UC Santa Barbara's Brain Imaging Center.

20 Apr 2011

Cognitive behavior therapy eases depressive symptoms, improves cardiovascular health in diabetics

Frequently, depression and diabetes go hand in hand. And depression can be a major obstacle for people living with diabetes, making it less likely they'll stick to a medicine schedule or exercise regimen.

20 Apr 2011

Tissue Genesis commences PVD clinical trials with adipose-derived adult stem cell-coated vascular grafts

Tissue Genesis, Inc., an emerging leader in adult stem cell and regenerative medicine, announced today that it has begun clinical trials for peripheral vascular disease (PVD) with adipose (fat) derived adult stem cell-coated vascular grafts at the University of Louisville Hospital. Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

Sustained participation of older people can prevent falls in care home and hospital settings

New research has indicated that more should be done to involve older people with interventions to prevent falls in care home and hospital settings.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

First hand transplant in western United States

Ms Emily Fennell, a 26-year-old California woman became the first person in the western United States to receive a hand transplant.

19 Apr 2011

African AIDS drug trial stopped prematurely

One of the studies in three African countries where women were given an AIDS drug to prevent HIV infection is being stopped because the project is not working, researchers said Monday. These women on the trial were taking a daily dose of the drug Truvada or a look-alike placebo pill and had an equal chance of becoming infected. The ones taking Truvada were expected to have had a much lower infection rate.

19 Apr 2011

RaySearch receives order for its RayStation system from RISO

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from RISO, the Radiotherapeutic Institute in Deventer, the Netherlands.

19 Apr 2011

Pupil measurements can predict patients' response to cognitive therapy

The scientific foundation of psychiatry is growing rapidly, yet it is a branch of medicine distinctive for the relative absence of biological tests in routine clinical practice.

19 Apr 2011

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.

19 Apr 2011

Novartis NVA23 Phase III trial in COPD achieves primary end point

Sosei Group Corporation announces that NVA237, a long-acting muscarinic antagonist being investigated as a once daily treatment for chronic obstructive pulmonary disease, achieved its primary end point in a Phase III study.

19 Apr 2011

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Many genes that cause human diseases have parallel genes in other organisms, including yeast. Now Columbia University researchers have used an innovative yeast-based screening method to identify a possible treatment for the fatal childhood disease Niemann-Pick C.

19 Apr 2011

Therapy News and Research

Testosterone therapy for prostate cancer needs reevaluation: New study

Whole-genome sequencing could soon improve cancer survival rates

Minimizing neurological side effects in high-grade glioma patients may improve survival

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Scientists detect several biomarkers to screen active drugs for Batten disease

Rituxan receives FDA approval for treating two rare diseases

Combination therapy restores skilled use of limb in rodent model

Flexibility of the brain can predict learning capability

Cognitive behavior therapy eases depressive symptoms, improves cardiovascular health in diabetics

Tissue Genesis commences PVD clinical trials with adipose-derived adult stem cell-coated vascular grafts

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Sustained participation of older people can prevent falls in care home and hospital settings

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

First hand transplant in western United States

African AIDS drug trial stopped prematurely

RaySearch receives order for its RayStation system from RISO

Pupil measurements can predict patients' response to cognitive therapy

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

Novartis NVA23 Phase III trial in COPD achieves primary end point

Exacerbate-reverse' approach can identify potential therapy for fatal childhood disease

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News